The microcatheter that started it all, offering trusted precision and effectiveness.
Engineered and precision-crafted in our state-of-the-art facilities
Pressurized viscodilation with catheterization across the entire 360° of the conventional outflow pathway.
What I like best about the iTrack™ system is that it doesn’t destroy future options for glaucoma treatment. I can do any other glaucoma treatment that I want to after iTrack™. With other treatments, that's not true. Once you scar down a lot of conjunctiva you've reduced your options. Or, you open up the canal a lot and you'll scar closed. You can't put a device in that space.
Robert Noecker, MD (USA)
The problem for me is that we don't know where the resistance to outflow is preoperatively. Is it the trabecular meshwork? Is it the Schlemm's canal? Are the distal channels working well or not? With iTrack™, there's no need to target a specific procedure or specific device into one part of the canal because we're opening up the entire system. It’s kind of like hedging our bets.
Inder P. Singh, MD (USA)
I view the angle as the new conjunctiva, because I want to manipulate it today – but I also want to preserve tissue. We all know that, in glaucoma, there's not a single procedure that lasts forever. I want to be able to come back and treat the patient with SLT over 360 degrees. I want to be able to implant micro stents in the future, or even try to rejuvenate the system again with another iTrack™ procedure.
Mark J. Gallardo, MD (USA)
Over two decades of excellence with iTrack™
The iTrack™ Advance has a CE Mark (Conformité Européenne) 2862 and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma.
INDICATIONS (International): The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open angle glaucoma.
CONTRAINDICATIONS (International): The iTrack™ Advance is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: Neovascular glaucoma; Angle-closure glaucoma; Previous surgery with resultant scarring of Schlemm’s canal.
ADVERSE EVENTS (International): Possible adverse events with the use of the iTrack™ Advance include, but are not limited to: hyphema, elevated IOP, Descemet’s membrane detachment, shallow or flat anterior chamber, hypotony, trabecular meshwork rupture, choroidal effusion, Peripheral Anterior Synechiae (PAS) and iris prolapse.
PRECAUTIONS (International): The iTrack™ Advance should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.
For full safety information, visit: https://itrack-advance.com
© 2026. Nova Eye, Inc. E&OE. Patents pending and/or granted.
iTrack™ Advance, iTrack™, ViscoInjector™ and iLumin™ are trademarks of Nova Eye,Inc.
The iTrack™ has a CE Mark (Conformité Européenne) 2862 and US Food and Drug Administration (FDA) 510(k) #K080067 for the treatment of open-angle glaucoma.
INDICATIONS: The iTrack™ canaloplasty microcatheter is cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma.
CONTRAINDICATIONS: The iTrack™ canaloplasty microcatheter is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: neovascular glaucoma; angle closure glaucoma; and, previous surgery with resultant scarring of Schlemm’s canal.
ADVERSE EVENTS: Possible adverse events with the use of the iTrack™ canaloplasty microcatheter include, but are not limited to: hyphema, elevated IOP, Descemet’s membrane detachment, shallow or flat anterior chamber, hypotony, trabecular meshwork rupture, choroidal effusion, Peripheral Anterior Synechiae (PAS) and iris prolapse.
WARNINGS: The iTrack™ canaloplasty microcatheter is intended for one time use only. DO NOT re-sterilize and/or reuse, as this can compromise device performance and increase the risk of cross contamination due to inappropriate reprocessing.
PRECAUTIONS: The iTrack™ canaloplasty microcatheter should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.
